Trade Supernus Pharmaceuticals Inc - SUPN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.15 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 34.53 |
| Open | 34.3 |
| 1-Year Change | 22.46% |
| Day's Range | 32.98 - 34.3 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 32.98 | -1.59 | -4.60% | 34.57 | 34.64 | 32.90 |
| Feb 20, 2025 | 34.53 | 1.05 | 3.14% | 33.48 | 34.55 | 33.36 |
| Feb 19, 2025 | 33.43 | 0.79 | 2.42% | 32.64 | 35.22 | 32.64 |
| Feb 18, 2025 | 39.63 | 0.69 | 1.77% | 38.94 | 39.90 | 38.70 |
| Feb 14, 2025 | 39.06 | -0.17 | -0.43% | 39.23 | 39.49 | 38.94 |
| Feb 13, 2025 | 39.43 | 1.42 | 3.74% | 38.01 | 39.48 | 38.01 |
| Feb 12, 2025 | 38.93 | 0.64 | 1.67% | 38.29 | 39.40 | 38.00 |
| Feb 11, 2025 | 38.57 | 0.93 | 2.47% | 37.64 | 38.60 | 37.55 |
| Feb 10, 2025 | 37.86 | -0.36 | -0.94% | 38.22 | 38.22 | 37.35 |
| Feb 7, 2025 | 38.35 | -0.29 | -0.75% | 38.64 | 38.72 | 37.96 |
| Feb 6, 2025 | 38.79 | -0.41 | -1.05% | 39.20 | 39.45 | 38.66 |
| Feb 5, 2025 | 39.43 | -0.62 | -1.55% | 40.05 | 40.05 | 39.29 |
| Feb 4, 2025 | 39.93 | 1.48 | 3.85% | 38.45 | 40.19 | 38.45 |
| Feb 3, 2025 | 37.31 | -0.28 | -0.74% | 37.59 | 37.88 | 36.07 |
| Jan 31, 2025 | 38.30 | -0.19 | -0.49% | 38.49 | 38.82 | 38.28 |
| Jan 30, 2025 | 38.64 | -0.38 | -0.97% | 39.02 | 39.41 | 38.52 |
| Jan 29, 2025 | 38.94 | 0.46 | 1.20% | 38.48 | 39.27 | 38.48 |
| Jan 28, 2025 | 39.08 | -0.13 | -0.33% | 39.21 | 39.56 | 38.82 |
| Jan 27, 2025 | 39.36 | 0.85 | 2.21% | 38.51 | 39.57 | 38.50 |
| Jan 24, 2025 | 38.50 | 0.26 | 0.68% | 38.24 | 39.21 | 38.23 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Supernus Company profile
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Supernus Pharmaceuticals Inc revenues increased 12% to $420.7M. Net income decreased 47% to $51M. Revenues reflect Net product sales- Trokendi XR segment increase of 34% to $231.5M, Net product sales-APOKYN segment increase of 70% to $73.3M. Net income was offset by Selling/General/Admin. Expense increase of 47% to $131.4M (expense), Advertising Expense increase of 58% to $59.7M (expense).
Equity composition
Common Stock $0.001 Par, 5/12, 62M auth., 23,912,319 issd. Insiders own approx. 6.73%. IPO:TBA
| Industry: | Proprietary & Advanced Pharmaceuticals |
9715 Key West Avenue
ROCKVILLE
MARYLAND 20850
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com